ACADIA to Host Conference Call and Webcast on Tuesday, May 8,2007, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—May 1, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the first quarterended March 31, 2007 on Tuesday, May 8, 2007, after the U.S. financialmarkets close. ACADIA's management will host a conference call andwebcast on Tuesday, May 8, 2007 at 5:00 p.m. Eastern Time to discussACADIA's financial results and development programs.
The conference call may be accessed by dialing 800-299-7928 forparticipants in the U.S. or Canada and 617-614-3926 for internationalcallers (reference passcode 99646143). A telephone replay of theconference call may be accessed through May 22, 2007 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 59529452). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until May 22, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive clinical programs as well as a portfolio of preclinical anddiscovery assets directed at large unmet medical needs, includingschizophrenia, Parkinson's disease psychosis, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.